peptide
Mazdutide
Weight lossalso known as IBI362, LY3305677
An investigational dual GLP-1 / glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly.
Currently in Phase III trials in China for chronic weight management and type 2 diabetes. Aims to combine the metabolic effects of GLP-1 receptor activation with glucagon-driven energy expenditure.
10 vendors with finnrick test grades. Higher grade = higher confirmed purity. Pricing data is pending for this peptide — grades below reflect independent purity testing.
| # | Vendor | Grade | Score | Tests | Reputation |
|---|---|---|---|---|---|
| 1 | Utherflag Great | A | 8.5 | 2 | 74 |
| 2 | Great | A | 8.2 | 3 | 72 |
| 3 | Peptide-Sflag Great | A | 7.9 | 4 | 72 |
| 4 | Great | A | 7.7 | 5 | 72 |
| 5 | Good | B | 6.9 | 2 | 71 |
| 6 | Polaris Peptideslogin required Good | B | 6.1 | 3 | 73 |
| 7 | Okay | C | 5.3 | 3 | 55 |
| 8 | Okay | C | 5.0 | 3 | 50 |
| 9 | Unrated | X | 6.8 | 1 | 59 |
| 10 | Bad | E | 4.0 | 2 | 54 |
Grades sourced from finnrick.com. Grade A = highest confidence in purity based on independent lab testing. Score is averaged across 28 individual tests.